Takam Kamga

Immune checkpoint inhibitors (ICIs) are pharmaceutical agents capable of disrupting immune checkpoint signaling, leading to T-cell activation and a robust anti-tumor response [1]. The first anti-cancer ICI was aimed at targeting Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA4) (Ipilimumab). It showed promising outcomes in pre-treated patients with melanoma, including anticancer response rates and improved overall survival (OS) [1].

Lung cancer remains the leading cause of cancer-related death worldwide (1). However, in recent years, there have been significant advancements in patient prognosis, primarily due to the discovery of a variety of therapeutic options. These include targeted therapies such as tyrosine kinase inhibitors (TKIs), immunotherapy with immune checkpoint inhibitors (ICIs), treatment combinations, and new treatment schedules for conventional therapies (2).

Dohner, H. et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet . Blood 115, 453–474 (2010). Kubo, H. et al. Identification of mesenchymal stem cell (MSC)-transcription factors by microarray and knockdown analyses, and signature molecule-marked MSC in bone marrow by immunohistochemistry . Genes Cells 14, 407–424 (2009). Pearce, D. J. et al.